Document Type : Review Articles
Authors
1
ksa, Ministry of Health, King Fahad Hospital in jazan
2
ksa, Ministry of Health, PMNH in Jazan
3
ksa, Ministry of Health, GAZAN HEALTH CLUSTER
4
ksa, Ministry of Health, Jazan Health Cluster
5
ksa, Ministry of Health, Prince Mohammed Bin Nasser Hospital
6
ksa, Ministry of Health, al-edabi general hospital
7
ksa, Ministry of Health
8
ksa, Ministry of Health, Nafi general hospital
9
ksa, Ministry of Health, Al-Baidh Primary Health Care Center
Abstract
Background:
mRNA vaccine technology represents a groundbreaking advancement in biomedicine, achieving global prominence for its pivotal role in mitigating the COVID-19 pandemic. While its success in infectious disease prevention is widely recognized, emerging evidence highlights its vast potential in addressing non-infectious diseases, including cancer, autoimmune disorders, and rare genetic conditions. These developments underscore the transformative capacity of mRNA vaccines to revolutionize therapeutic paradigms and fill critical gaps in medical treatment.
Aim:
This paper aims to explore the expanding frontiers of mRNA vaccine technology, focusing on its applications beyond infectious diseases. Specifically, it evaluates the underlying mechanisms, recent technological advancements, and emerging therapeutic domains, while also addressing existing challenges and identifying priorities for future research.
Methods:
This review synthesizes data from recent preclinical and clinical studies conducted between 2020 and 2024. It examines advancements in mRNA design, delivery systems, and production scalability, alongside the application of mRNA platforms in oncology, autoimmune diseases, and genetic disorders. Sources include peer-reviewed journals, clinical trial reports, and expert reviews, ensuring a comprehensive and critical analysis of the current landscape.
Results:
Advances in mRNA technology, including lipid nanoparticle delivery systems and nucleoside modifications, have significantly enhanced vaccine efficacy and stability. Preclinical and clinical studies demonstrate promising outcomes in the development of personalized cancer vaccines, immune tolerance induction for autoimmune disorders, and protein replacement therapies for rare genetic conditions. Despite these achievements, challenges persist in areas such as cost-effective manufacturing, immunogenicity control, and regulatory standardization.
Conclusion:
mRNA vaccine technology has emerged as a versatile and dynamic platform, poised to address unmet medical needs in diverse therapeutic areas. Its adaptability and precision offer unparalleled opportunities for personalized medicine and disease prevention. However, realizing its full potential requires overcoming current limitations through interdisciplinary research and innovation. Collaborative efforts involving academia, industry, and regulatory bodies are essential to accelerate clinical translation and broaden access to these cutting-edge therapies.
Keywords
Main Subjects
)
View on SCiNiTO